Por: CNBC Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA sequencing company to Icahn's sharp criticism of the $7.1 billion deal it completed in 2021, saying it's committed to maximizing shareholder value as it works... + full article
CNBC USA Health March 24, 2023
In this articleCarl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan CNBCCarl Icahn on Friday alleged that 's directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer... + más
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
CNBC USA Business March 18, 2023
Business: develops, manufactures and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and Grail. Grail, which was acquired in , is a health-care company focused on early detection of... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
Business Insider USA Business December 14, 2022
Carl Icahn had a textbook strategy for the Nevada-based energy utility Southwest Gas Holdings. The legendary activist investor purchased almost 5% of the company's shares in late 2021 and publicly , winning four of its 11 board seats, the ouster of its chief executive, and... + más
Carl Icahn says he still thinks we are in a bear market despite Thursday's rally | CNBC
Carl Icahn snaps up shares of canning giant Crown. Here’s how he may build value | CNBC
Los Angeles Times USA Business November 16, 2022
San Diego’s Illumina said this week that it will trim its global workforce by 5% amid economic headwinds that have slowed orders and are expected to linger into 2023. The gene sequencing market leader, which employs about 9,200 workers worldwide, declined to say how many... + más
The era of fast, cheap genome sequencing is here | Ars Technica
Illumina: Q4 Earnings Snapshot | Associated Press
CNBC USA Business November 11, 2022
Famed investor Carl Icahn said Thursday's relief rally didn't change his negative view on the market, and he believes a recession is still on the horizon.We keep our portfolio hedged, Icahn said on CNBC's Thursday. I am still very, quite bearish on what is going... + más
The Rare Treasures Of The Fabergé Workshop At GemGenève | Forbes
CNBC USA Business November 05, 2022
Business: is a worldwide leader in the design, manufacture and sale of packaging products for consumer goods and industrial products. They operate in three segments: Beverage, which accounts for roughly 70% of earnings before interest, taxes, depreciation, and amortization;... + más
Liz Truss Is Now the Shortest-Serving Leader in U.K. History | Time
Ars Technica USA Science October 01, 2022
Navigate Filter by topic Settings Front page layout Site theme Comment activity Sign up or login to join the discussions! Sign up to comment and more - Oct 1, 2022 11:17 am UTC / Illumina says its NovaSeq X machine will get the price of sequencing down to $200 per human... + más
The best budget laptop of 2022 | The Verge
Starting a Revolution Isn’t Enough | The Atlantic
About iurex | Privacy Policy | Disclaimer |